【重磅】胆管癌首款靶向治疗药物-培美替尼

Pemetimib, a new targeted treatment for cholangiocarcinoma, was first developed by Incyte Biopharmaceutical Company in the United States. In September 2018, with the support of the drug regulatory department and the US Food and Drug Administration (FDA), Incyte signed an agreement with Foundation Pharmaceuticals, a company engaged in tumor genetic testing, to jointly develop pemetimib for the treatment of cholangiocarcinoma, so as to promote the approval of marketing, production, sales and commercialization by the drug regulatory authorities as soon as possible. In December 2018, Incyte also reached a strategic cooperation agreement with China's Suzhou Innovent Biopharmaceutical Company to jointly develop three anti-tumor drug candidates in clinical trials. Innovent Biopharmaceutical Company will have the development and commercialization rights of pemetinib and two other candidate drugs in mainland China, Hong Kong, China, Macau, and Taiwan. On April 17, 2020, the U.S. FDA accelerated the approval of pemetinib tablets for marketing, with the trade name PemazyreR. Becoming the world's first targeted drug for the treatment of cholangiocarcinoma.

Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.